Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-066384
Filing Date
2025-05-08
Accepted
2025-05-08 07:24:46
Documents
62
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q cgem-20250331.htm   iXBRL 10-Q 1573415
2 EX-10.1 cgem-ex10_1.htm EX-10.1 20119
3 EX-10.2 cgem-ex10_2.htm EX-10.2 20517
4 EX-31.1 cgem-ex31_1.htm EX-31.1 15522
5 EX-31.2 cgem-ex31_2.htm EX-31.2 15298
6 EX-32.1 cgem-ex32_1.htm EX-32.1 14277
  Complete submission text file 0000950170-25-066384.txt   7513807

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT cgem-20250331.xsd EX-101.SCH 1172422
65 EXTRACTED XBRL INSTANCE DOCUMENT cgem-20250331_htm.xml XML 1364894
Mailing Address ONE MAIN STREET SUITE 1350 CAMBRIDGE MA 02142
Business Address ONE MAIN STREET SUITE 1350 CAMBRIDGE MA 02142 617-410-4650
Cullinan Therapeutics, Inc. (Filer) CIK: 0001789972 (see all company filings)

EIN.: 813879991 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39856 | Film No.: 25923863
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)